The Rational Design of a Novel Potent Analogue of the 5′-AMP-Activated Protein Kinase Inhibitor Compound C with Improved Selectivity and Cellular Activity

Citation

Machrouhi, F., Ouhamou, N., Laderoute, K., Calaoagan, J., Bukhtiyarova, M., Ehrlich, P. J., & Klon, A. E. (2010). The rational design of a novel potent analogue of the 5′-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorganic & medicinal chemistry letters, 20(22), 6394-6399.

Abstract

We have designed and synthesized analogues of compound C, a non-specific inhibitor of 5′-AMP-activated protein kinase (AMPK), using a computational fragment-based drug design (FBDD) approach. Synthesizing only twenty-seven analogues yielded a compound that was equipotent to compound C in the inhibition of the human AMPK (hAMPK) α2 subunit in the heterotrimeric complex in vitro, exhibited significantly improved selectivity against a subset of relevant kinases, and demonstrated enhanced cellular inhibition of AMPK.


Read more from SRI

  • Banner and attendees at the IEEE Hard Tech Venture Summit

    Cultivating hard tech startups that scale

    IEEE’s Hard Tech Venture Summit convened innovators at SRI to refine strategies and build new networks.

  • Patient going into a MRI

    Bringing surgical tools inside the MRI

    Drawing on SRI’s unique innovation ecosystem, the startup Medical Devices Corner is seeking to improve cancer surgery by advancing MRI-safe teleoperation.

  • Christopher Mims and Susan Patrick

    PARC Forum: How to AI

    The Wall Street Journal tech columnist Christopher Mims and SRI Education’s Susan Patrick discuss how AI can strengthen human agency.